82VS is a venture studio that builds capital-efficient, asset-focused drug companies by providing unique access to Alloy Therapeutics’ robust suite of discovery platforms and services across antibodies, bispecifics, TCR mimics, and genetic medicines. They collaborate and co-build companies, supporting entrepreneurial success from concept to Series A with their expert support in strategy and R&D funding.
Deal activity and portfolio updates would appear here
Connect your data source to see recent transactions